The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders
The important task of nevrology is to improve the diagnosis of chronic progressive degenerative and vascular brain diseases – to detect them at the earliest stages. The paper presents current views on the non-dementia stages of brain diseases: moderate, mild, and subjective cognitive impairments. It...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2016-01-01
|
| Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/564 |
| id |
doaj-c804477e49a0468ab1991ca182319242 |
|---|---|
| record_format |
Article |
| spelling |
doaj-c804477e49a0468ab1991ca1823192422021-07-29T08:58:36ZrusIMA-PRESS LLCNevrologiâ, Nejropsihiatriâ, Psihosomatika2074-27112310-13422016-01-0174839110.14412/2074-2711-2015-4-83-91524The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disordersV. V. Zakharov0N. V. Vakhnina1D. O. Gromova2N. E. Ter-Ovanesova3A. V. Tarapovskaya4I.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaI.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaThe important task of nevrology is to improve the diagnosis of chronic progressive degenerative and vascular brain diseases – to detect them at the earliest stages. The paper presents current views on the non-dementia stages of brain diseases: moderate, mild, and subjective cognitive impairments. It sets forth data on their prevalence and clinical features and types, as well as international diagnostic criteria. There is evidence for the expediency of the earliest neuroprotective therapy to prevent dementia. A methodology for neuroprotective therapy is discussed; the available data on the long-term effect of intermittent treatment cycles with the vasotropic and neurometabolic drug tanakan are given.https://nnp.ima-press.net/nnp/article/view/564cognitive impairmentsdementia preventionneuroprotective therapy |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
V. V. Zakharov N. V. Vakhnina D. O. Gromova N. E. Ter-Ovanesova A. V. Tarapovskaya |
| spellingShingle |
V. V. Zakharov N. V. Vakhnina D. O. Gromova N. E. Ter-Ovanesova A. V. Tarapovskaya The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders Nevrologiâ, Nejropsihiatriâ, Psihosomatika cognitive impairments dementia prevention neuroprotective therapy |
| author_facet |
V. V. Zakharov N. V. Vakhnina D. O. Gromova N. E. Ter-Ovanesova A. V. Tarapovskaya |
| author_sort |
V. V. Zakharov |
| title |
The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders |
| title_short |
The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders |
| title_full |
The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders |
| title_fullStr |
The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders |
| title_full_unstemmed |
The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders |
| title_sort |
clinical spectrum of non-dementia cognitive impairment: subjective mild-to-moderate disorders |
| publisher |
IMA-PRESS LLC |
| series |
Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
| issn |
2074-2711 2310-1342 |
| publishDate |
2016-01-01 |
| description |
The important task of nevrology is to improve the diagnosis of chronic progressive degenerative and vascular brain diseases – to detect them at the earliest stages. The paper presents current views on the non-dementia stages of brain diseases: moderate, mild, and subjective cognitive impairments. It sets forth data on their prevalence and clinical features and types, as well as international diagnostic criteria. There is evidence for the expediency of the earliest neuroprotective therapy to prevent dementia. A methodology for neuroprotective therapy is discussed; the available data on the long-term effect of intermittent treatment cycles with the vasotropic and neurometabolic drug tanakan are given. |
| topic |
cognitive impairments dementia prevention neuroprotective therapy |
| url |
https://nnp.ima-press.net/nnp/article/view/564 |
| work_keys_str_mv |
AT vvzakharov theclinicalspectrumofnondementiacognitiveimpairmentsubjectivemildtomoderatedisorders AT nvvakhnina theclinicalspectrumofnondementiacognitiveimpairmentsubjectivemildtomoderatedisorders AT dogromova theclinicalspectrumofnondementiacognitiveimpairmentsubjectivemildtomoderatedisorders AT neterovanesova theclinicalspectrumofnondementiacognitiveimpairmentsubjectivemildtomoderatedisorders AT avtarapovskaya theclinicalspectrumofnondementiacognitiveimpairmentsubjectivemildtomoderatedisorders AT vvzakharov clinicalspectrumofnondementiacognitiveimpairmentsubjectivemildtomoderatedisorders AT nvvakhnina clinicalspectrumofnondementiacognitiveimpairmentsubjectivemildtomoderatedisorders AT dogromova clinicalspectrumofnondementiacognitiveimpairmentsubjectivemildtomoderatedisorders AT neterovanesova clinicalspectrumofnondementiacognitiveimpairmentsubjectivemildtomoderatedisorders AT avtarapovskaya clinicalspectrumofnondementiacognitiveimpairmentsubjectivemildtomoderatedisorders |
| _version_ |
1721250771666731008 |